CCR4 acts as a prominent biomarker expressed in the skin lesions of MF and its inhibition by monoclonal antibody mogamulizumab has proven to be an effective therapy for advanced MF [24,25]. The gene discussed is CCR4; the disease is mycosis fungoides.